A NEW STRONGER OZEMPIC IS COMING. HERE'S WHAT TO KNOW

Summary from the TLDR newsletter

Novo Nordisk's CagriSema combines semaglutide, the active ingredient in Ozempic and Wegovy, with an amylin and calcitonin receptor agonist. Amylin helps regulate blood sugar levels while calcitonin controls calcium levels in the blood. An early-stage clinical trial of CagriSema found it helped patients lose more weight faster compared to the highest dose of Wegovy. Late-stage trials of the drug are expected later this year and in the first half of 2025.